CBD Research Roundup

Image | adobe.stock/Near

Recent Study Finds THC Labeling More Accurate in Concentrate Products Than Cannabis Flower

According to a recent study titled, “Accuracy of labeled THC potency across flower and concentrate cannabis products”, research showed that out of the cannabis flower products that were tested, 56.7% of them were within 15% of their tetrahydrocannabinol (THC) content listed on their product label. Regarding concentrate products, research found that 96% of these products were within 15% of the THC content on their label.

Study Examines Increasing Cannabis Vaping Trends in US Adolescents

A recently published study analyzed cannabis vaping trends in the US among adolescents, looking at THC, CBD, and synthetic cannabinoids (SC) individually. The researchers also focused on the importance of continuous data collection and monitoring in order to provide public health information to adolescents on the health impacts of vaping. The study, “Adolescent Cannabis Vaping Trends (2021–2023): Delta-9-Tetrahydrocannabinol, Cannabidiol, and Synthetic Cannabinoids,” was published in the American Journal of Preventive Medicine on June 30, 2025.

CBD Gummies Study Reveals Inconsistent Product Labeling

Researchers from the University of Kentucky (Lexington, Kentucky), conducted a study recently that confirmed that the cannabis industry is still experiencing inaccurate product labeling. The study focused particularly on the cannabinoid, cannabidiol (CBD), and investigated 56 CBG gummy products that were available for purchase online from a variety of brands. To analyze the products selected researchers utilized liquid chromatography-tandem mass spectrometry (LC-MS-MS).

Study Demonstrates Antifungal Activity of Two Cannabinoids

A recently published study examined the effects of two cannabinoids on different fungal pathogens and sought to explain their mechanism of action. The researchers highlighted results on the pathogen Cryptococcus neoformans, which is listed by the World Health Organization (WHO) as a Critical Priority pathogen. As noted in the abstract, the rise antifungal resistance has been seen globally, yet there is a lack of planned clinical development of new antifungal drugs. The study, “Uncovering the antifungal potential of Cannabidiol and Cannabidivarin,” was published in June 2025 in PLOS Neglected Tropical Diseases.

Study Aims to Optimize CBD Absorption and Solubility for Enhanced Therapeutic Use

A recently published study (1) aimed to improve the solubility and permeability of oral CBD in order to increase therapeutic effects, including pain and anxiety relief and inflammation reduction, when treating conditions such as epilepsy, multiple sclerosis, and Alzheimer’s. As noted in the study’s abstract, the poor water solubility, low GI permeability, and chemical instability of CBD reduce its potential benefits. Researchers at the University of South Australia (UNISA) sought to create a CBD–phospholipid complex as an improved delivery system of CBD. The study, “Optimising Cannabidiol Delivery: Improving Water Solubility and Permeability Through Phospholipid Complexation,” was published in March 2025 in the International Journal of Molecular Sciences.